Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Active not recruiting 5Not yet recruiting 3Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 2Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Carboplatin 126Cisplatin 125Drug Therapy 104Bevacizumab 98Oxaliplatin 97Capecitabine 96Radiotherapy 94Gemcitabine 87Paclitaxel 85tislelizumab 84Cyclophosphamide 83Specimen Handling 80pembrolizumab 76toripalimab 67Magnetic Resonance Spectroscopy 63Injections 62Fluorouracil 62sintilimab 57anlotinib 53Surgical Procedures, Operative 50130-nm albumin-bound paclitaxel 50Docetaxel 49fludarabine 46Pemetrexed 45Standard of Care 43venetoclax 42Leucovorin 42Biopsy 42Irinotecan 41lenvatinib 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × Imlunestrant × Clear all
NCT07287098 2026-05-22

preEMBER

Eli Lilly and Company

Phase 2 Not yet recruiting
600 enrolled
Breast

Breast Neoplasms

NCT07410559 2026-02-18

Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer

Fudan University

Phase 2 Not yet recruiting
189 enrolled
Breast

Breast Neoplasms

NCT07191717 2025-11-10

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

Jonsson Comprehensive Cancer Center

Phase 2 Not yet recruiting
42 enrolled
Breast

Anatomic Stage I Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡